A Phase 2 interventional study of AGMB-447 and Placebo in Idiopathic Pulmonary Fibrosis (IPF), sponsored by Agomab Spain S.L.U.. Not yet recruiting. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Agomab Spain S.L.U. (part of Agomab Therapeutics NV) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main goal of this clinical trial is to find out if an experimental inhaled drug, AGMB-447, can help improve lung function in people living with a lung disease called idiopathic pulmonary fibrosis (IPF). To do this, the effects of the study drug will be compared to a placebo, which is a treatment that looks like the study drug but contains no active medicine.
The specific goals of the trial are as follows:
Primary Objective and Estimand: The main goal is to see if 24 weeks of treatment with AGMB-447 helps the lungs work better than a placebo. This is measured by checking the total amount of air a person can forcefully blow out after taking a deep breath. The study will measure this effect for all participants who start the trial, regardless of whether they are able to finish the full 24 weeks of treatment or if they need to change their other medications during the study.
Secondary Objective: The trial also aims to measure how much of the study drug is in the blood at different times. This helps researchers understand how the drug is absorbed and processed by the body after it is inhaled. In addition, the trial aims to evaluate if the treatment is safe and well-tolerated.
This is a double-blind, randomized, placebo-controlled, multicenter Phase 2a trial to assess efficacy, safety, tolerability and pharmacokinetics (PK) of AGMB-447 compared to placebo in participants diagnosed with IPF over 24 weeks of treatment. The trial population will include adult participants aged ≥40 years with a confirmed diagnosis of IPF.
Approximately 120 eligible participants will be randomized in a 2:1 ratio to AGMB-447 or placebo group. Both AGMB-447 and placebo will be administered via inhalation.
The total duration of the trial for each participant will be up to approximately 32 weeks, consisting of a 4-week screening period, a 24-week treatment period, and a 4-week follow-up period.
After written informed consent is obtained, participants will enter a screening period of up to 28 days to assess eligibility.
Participants on an approved antifibrotic treatment should be on a stable dose for at least 8 weeks before the screening visit and throughout the screening period; or participants who are not on antifibrotic treatment should be stable for at least 4 weeks before the screening visit (treatment-naïve or intolerant).
At the end of the Treatment period, participants will enter a 4-week Follow-up period. The last trial visit (End of Study) for all participants will be on site, at the end of the Follow-up period.
Throughout the study, participants will undergo routine safety assessments at study visits, which will include physical examination, vital signs, clinical laboratory assessments, electrocardiogram (ECG), and recording of AEs.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.
This study's planned enrollment of 120 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Browse Idiopathic Pulmonary Fibrosis studies →Agomab Spain S.L.U. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
First submitted after Agomab Spain S.L.U. became part of Agomab Therapeutics NV.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed pulmonary function criteria at screening, as follows:
Exclusion Criteria:
Systemic or opportunistic infections including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AGMB-447
Matching Placebo
Drug: Placebo
Administered via inhalation
Matching placebo administered via inhalation
Change in Forced Vital Capacity (FVC) (mL)
To evaluate the effect of AGMB-447 on lung function in participants with IPF, compared to placebo
Time frame: At week 24 compared to baseline (Day 1)
Concentration of AGMB-447 and MET-093 metabolite in plasma
To characterize the systemic PK of AGMB-447 in participants with IPF
Time frame: From baseline to week 24
Incidence of Treatment Emergent Adverse Events (TEAEs)
To evaluate the safety and tolerability of AGMB-447 in participants with IPF, compared to placebo
Time frame: From baseline to week 24
Number of participants with abnormal clinical laboratory tests
To evaluate the safety and tolerability of AGMB-447 in participants with IPF, compared to placebo
Time frame: From baseline to week 24
Number of participants with abnormal ECG parameters
To evaluate the safety and tolerability of AGMB-447 in participants with IPF, compared to placebo
Time frame: From baseline to week 24
Number of participants with abnormal vital signs
To evaluate the safety and tolerability of AGMB-447 in participants with IPF, compared to placebo
Time frame: From baseline to week 24
Number of participants with abnormal physical examinations
To evaluate the safety and tolerability of AGMB-447 in participants with IPF, compared to placebo
Time frame: From baseline to week 24
Change in forced expiratory volume in 1 second (FEV1)
To evaluate the safety and tolerability of AGMB-447 in participants with IPF, compared to placebo
Time frame: From pre-dose to week 24
Change in forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC)
To evaluate the safety and tolerability of AGMB-447 in participants with IPF, compared to placebo
Time frame: From pre-dose to week 24
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Oct 2028, 23 months later.
Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's planned 23 months is below that.
Counting every sponsor, half of 76 studies reached it within 29 months; a quarter within 21 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Idiopathic Pulmonary Fibrosis →